55
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Signalling pathways of the TNF superfamily: a double-edged sword.

      Nature reviews. Immunology

      Animals, Autoimmune Diseases, drug therapy, immunology, Carrier Proteins, Humans, Ligands, Lymphotoxin-alpha, antagonists & inhibitors, Membrane Proteins, Mice, NF-kappa B, Receptors, Tumor Necrosis Factor, Signal Transduction, Tumor Necrosis Factor-alpha

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Two different tumour-necrosis factors (TNFs), first isolated in 1984, were found to be cytotoxic to tumour cells and to induce tumour regression in mice. Research during the past two decades has shown the existence of a superfamily of TNF proteins consisting of 19 members that signal through 29 receptors. These ligands, while regulating normal functions such as immune responses, haematopoiesis and morphogenesis, have also been implicated in tumorigenesis, transplant rejection, septic shock, viral replication, bone resorption, rheumatoid arthritis and diabetes; so indicating their role as 'double-edged swords'. These cytokines either induce cellular proliferation, survival, differentiation or apoptosis. Blockers of TNF have been approved for human use in treating TNF-linked autoimmune diseases in the United States and other countries.

          Related collections

          Author and article information

          Journal
          12949498
          10.1038/nri1184

          Comments

          Comment on this article